Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Drug Type
- Biotech
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- Conditions
- Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-05-13
- Target Recruit Count
- 32
- Registration Number
- NCT06385873
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06378242
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳West China Hospital, Chengdu, Sichuan, China
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Conditions
- First-line TreatmentHER2-positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Target Recruit Count
- 312
- Registration Number
- NCT06278870
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 63
- Registration Number
- NCT06233864
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT06227325
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06227156
- Locations
- 🇨🇳
The Third Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Conditions
- Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06221748
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, China
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
- Conditions
- Upper Urinary Tract Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06210490
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
- Conditions
- HER-2 Protein OverexpressionNon-muscle Invasive Bladder Cancer
- Interventions
- Drug: Bacillus Calmette Guerin Vaccine
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06187506
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
- Conditions
- Disitamab VedotinERBB2 Mutation-Related TumorsNon Small Cell Lung CancerERBB2 Gene Duplication
- Interventions
- Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2023-12-29
- Target Recruit Count
- 108
- Registration Number
- NCT06185400
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.